Cargando…

Safety and tolerability of ceftobiprole

Ceftobiprole is a fifth generation cephalosporin with a series of characteristics differentiating it from other beta-lactams, including its antibacterial activity, mainly against methicillin-resistant Staphylococcus aureus, resistant Streptococcus pneumoniae and also Gram-negative microorganisms suc...

Descripción completa

Detalles Bibliográficos
Autor principal:	Grau, Santiago
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedad Española de Quimioterapia 2019
Materias:	Ceftobiprole Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6755348/ https://www.ncbi.nlm.nih.gov/pubmed/31364340

Ejemplares similares

Ceftobiprole for the treatment of pneumonia
por: Cillóniz, Catia, et al.
Publicado: (2019)

Possible clinical indications of ceftobiprole
por: Barberán, José
Publicado: (2019)

Ceftobiprole: pharmacokinetics and PK/PD profile
por: Azanza Perea, José Ramón, et al.
Publicado: (2019)

Mechanisms of action and antimicrobial activity of ceftobiprole
por: Morosini, María-Isabel, et al.
Publicado: (2019)

Ceftobripole: Experience in staphylococcal bacteremia
por: Soriano, Alex, et al.
Publicado: (2019)

Introduction
por: Llinares, Pedro, et al.
Publicado: (2019)

Pharmacokinetics and Safety of Ceftobiprole in Pediatric Patients
por: Rubino, Christopher M., et al.
Publicado: (2021)

Ceftobiprole medocaril
por: Méndez, Raúl, et al.
Publicado: (2022)

Ceftobiprole for the treatment of pneumonia: a European perspective
por: Liapikou, Adamantia, et al.
Publicado: (2015)

Ceftobiprole Perspective: Current and Potential Future Indications
por: Lupia, Tommaso, et al.
Publicado: (2021)

Ceftobiprole: a clinical view
por: Pérez-Crespo, Pedro María Martínez, et al.
Publicado: (2021)

Emerging agents to combat complicated and resistant infections: focus on ceftobiprole
por: Bustos, César, et al.
Publicado: (2010)

Resistance and the management of complicated skin and skin structure infections: the role of ceftobiprole
por: Barbour, April, et al.
Publicado: (2010)

Pharmacokinetics, pharmacodynamics, and safety of single- and multiple-dose intravenous ceftobiprole in healthy Chinese participants
por: Li, Wan-Zhen, et al.
Publicado: (2021)

In Vitro Activity of Tedizolid, Dalbavancin, and Ceftobiprole Against Clostridium difficile
por: Binyamin, Dana, et al.
Publicado: (2018)

Pharmacokinetics and Target Attainment of Ceftobiprole in Asian and Non‐Asian Subjects
por: Muller, A. E., et al.
Publicado: (2018)

Model-Based Approach for Optimizing Ceftobiprole Dosage in Pediatric Patients
por: Rubino, Christopher M., et al.
Publicado: (2021)

Pharmacokinetics and Dosing of Ceftobiprole Medocaril for the Treatment of Hospital- and Community-Acquired Pneumonia in Different Patient Populations
por: Torres, Antonio, et al.
Publicado: (2016)

Ceftobiprole for Treatment of MRSA Blood Stream Infection: A Case Series
por: Mahmoud, Ebrahim, et al.
Publicado: (2020)

Ceftobiprole: a potential empirical post-operative monotherapy in prosthetic joint infections
por: Duployez, Claire, et al.
Publicado: (2020)

No Evidence for Ceftobiprole-Induced Immune Hemolytic Anemia in Three Phase 3 Clinical Trials
por: Hamed, Kamal, et al.
Publicado: (2020)

In vitro activity of ceftobiprole and comparator antibiotics against contemporary European isolates (2016–19)
por: Canton, Rafael, et al.
Publicado: (2022)

Synergistic Combinations of FDA-Approved Drugs with Ceftobiprole against Methicillin-Resistant Staphylococcus aureus
por: Sharma, Amar Deep, et al.
Publicado: (2022)

Ampicillin and Ceftobiprole Combination for the Treatment of Enterococcus faecalis Invasive Infections: “The Times They Are A-Changin”
por: Giuliano, Simone, et al.
Publicado: (2023)

Susceptibility to ceftobiprole of respiratory-tract pathogens collected in the United Kingdom and Ireland during 2014–2015
por: Santerre Henriksen, Anne, et al.
Publicado: (2018)

Ceftobiprole Activity When Tested Against Contemporary Bacteria Causing Bloodstream Infections in the US (2016)
por: Flamm, Robert K, et al.
Publicado: (2017)

No Evidence for Ceftobiprole-Induced Immune Hemolytic Anemia in Three Phase 3 Clinical Trials [Erratum]
Publicado: (2020)

Ceftobiprole Medocaril Is an Effective Post-Exposure Treatment in the Fischer 344 Rat Model of Pneumonic Tularemia
por: Hahn, Mark M., et al.
Publicado: (2023)

2561. Population Pharmacokinetic Analyses for Ceftobiprole Using Data from Phase 1 and 3 Studies
por: Cammarata, Anthony P, et al.
Publicado: (2023)

Study of Degradation Kinetics and Structural Analysis of Related Substances of Ceftobiprole by HPLC with UV and MS/MS Detection
por: Boczar, Dariusz, et al.
Publicado: (2022)

Cefto Real-Life Study: Real-World Data on the Use of Ceftobiprole in a Multicenter Spanish Cohort
por: Hidalgo-Tenorio, Carmen, et al.
Publicado: (2023)

Early improvement in severely ill patients with pneumonia treated with ceftobiprole: a retrospective analysis of two major trials
por: Scheeren, Thomas W. L., et al.
Publicado: (2019)

Comparative activity of ceftobiprole against coagulase-negative staphylococci from the BSAC Bacteraemia Surveillance Programme, 2013–2015
por: Henriksen, Anne Santerre, et al.
Publicado: (2018)

1946. In Vitro Activity of Ceftobiprole against Staphylococcus aureus Bacteremia Isolates from the United States (2018–2020)
por: Duncan, Leonard R, et al.
Publicado: (2023)

1112. Ceftobiprole for the Treatment of Invasive Enterococcus faecalis Infections: Ampicillin, "Should I Stay or Should I Go?"
por: Giuliano, Simone, et al.
Publicado: (2023)

2162. In Vitro Antimicrobial Activity of Ceftobiprole against Streptococcus pneumoniae Isolates from the United States (2016–2020)
por: Duncan, Leonard R, et al.
Publicado: (2023)

Efficacy and safety of delafloxacin, ceftaroline, ceftobiprole, and tigecycline for the empiric treatment of acute bacterial skin and skin structure infections: A network meta-analysis of randomized controlled trials
por: Alhifany, Abdullah A., et al.
Publicado: (2022)

Genotypic Characterization of Methicillin-Resistant Staphylococcus aureus Recovered at Baseline from Phase 3 Pneumonia Clinical Trials for Ceftobiprole
por: Mendes, Rodrigo E., et al.
Publicado: (2016)

Ceftobiprole versus daptomycin in Staphylococcus aureus bacteremia: a novel protocol for a double-blind, Phase III trial
por: Hamed, Kamal, et al.
Publicado: (2020)

Impact of PBP4 Alterations on β-Lactam Resistance and Ceftobiprole Non-Susceptibility Among Enterococcus faecalis Clinical Isolates
por: Lazzaro, Lorenzo M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bet2p3o2pq3ctfh3to55qe2ahb